Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-reductase: Evidence for mechanism-based inhibition by finasteride

Journal of Steroid Biochemistry and Molecular Biology

Volumn 66, Issue 5-6, 1998, Pages 271-279

  Ellsworth, K P ^a   Azzolina, B A ^a   Cimis, G ^a   Bull, H G ^a   Harris, G S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; GENE EXPRESSION; MALE; MOLECULAR CLONING; NONHUMAN; PROSTATE HYPERTROPHY; RHESUS MONKEY;

AMINO ACID SEQUENCE; ANIMALS; CHOLESTENONE 5 ALPHA-REDUCTASE; CLONING, MOLECULAR; COS CELLS; ENZYME INHIBITORS; FINASTERIDE; GENE EXPRESSION; GENES; HUMANS; ISOENZYMES; KINETICS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; SUBSTRATE SPECIFICITY;

EID: 0031757991     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00059-4     Document Type: Article

References (34)

1. Wilson J. D., Griffin J. E. and Russell D. W., Steroid 5α-reductase 2 deficiency. Endocrin. Rev. 14 (1993) 577-593.
2. Gormley G. J., Stoner E., Bruskewitz R. C., ImperatoMcGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B., Tenover J. S., Baughan E. D., Pappas F., Taylor A., Binkowitz B., Ng J. and Group F. S., The effect of finasteride in men with benign prostatic hyperplasia. New Eng. J. Med. 327 (1992) 1185-1191.
3. Dallob A. L., Sadick N. S., Unger W., Lipert S., Geissler L. A., Gregoire S. L., Nguyen H. H., Moore E. C. and Tanaka W. K., The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J. Clin. Endocrinol. Metabol. 79 (1994) 703-706.
4. Moghetti P., Castello R., Magnani C. M., Tosi F., Negri C., Armanini D., Bellotti G. and Muggeo M., Clinical and hormonal effects of the 5α-reductase inhibitor finasteride in idiopathic hirsutism. J. Clin. Endocrinol. Metabol. 79 (1994) 1115-1121.
5. Kaufman, K. D., Clinical studies on the effects of oral finasteride, a type II 5α-reductase inhibitor, on scalp hair in men with male pattern baldness. In Hair Research for the NextMillennium, ed. D. J. Van Neste and V. A. Randall. Elsevier, Amsterdam, 1996, pp. 363-365.
6. Andersson S. and Russell D. W., Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 3640-3644.
7. Andersson S., Berman D. M., Jenkins E. P. and Russell D. W., Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354 (1991) 159-161.
8. Imperato-McGinley J., Guerrero L., Gautier T. and Peterson R. E., Steroid 5α-reductase deficiency in man: An inherited form of male pseudohermaphroditism. Science 27 (1974) 1213-1215.
9. Peterson R. E., Imperato-McGinley J., Gautier T. and Sturla E., Male pseudohermaphroditism due to steroid 5α-reductase deficiency. Am. J.Med. 62 (1977) 170-191.
10. Imperato-McGinley J. and Gautier T., Inherited 5α-reductase deficiency in man. Trends Genet. 2 (1986) 130-133.
11. Imperato-McGinley J., Gautier T., Cai L. Q., Yee B., Epstein J. and Pochi P., The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J. Clin. Endocrinol. Metabol. 76 (1993) 524-528.
12. Schwartz J. I., Hecken A. V., De Schepper P. J., De Lepeleire I., Lasseter K. C., Cooper Shamblen E., Winchell G. A., Constanzer M. L., Chavez C. M., Wang D. Z., Ebel D. L., Justice S. J. and Gertz B. J., Effect of MK-386, a novel inhibitor of type 1 5α-reductase, alone and in combination with finasteride, on serum DHT (dihydrotestosterone) concentrations in men. J. Clin. Endocrinol. Metabol. 81 (1996) 2942-2947.
13. Stoner E., 5α-reductase inhibitors/Finasteride. Prostate 6 (1996) 82-87.
14. Clark R. L., Anderson C. A., Prahalada S., Robertson R. T., Lochry E. A., Leonard Y. M., Stevens J. L. and Hoverman A. M., Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5α-reductase inhibitor. Toxicol. Appl. Pharmacol. 119 (1993) 34-40.
15. Clark R. L., Antonello J. M., Grossman S. J., Wise L. D., Anderson C., Bagdon W. J., Prahalada S., MacDonald J. S. and Robertson R. T., External genitalia abnormalities in male rats exposed in utero to finasteride, a 5α-reductase inhibitor. Teratology 42 (1990) 91-100.
16. Azzolina, B. A., Ellsworth, K. P., Geissler, W., Andersson, S. and Harris, G. S., Inhibition of rat 5α-reductases by finasteride: Evidence for isozyme differences in the mechanism of inhibition. J. Steroid Biochem. Mol. Biol., 61 (1997) 55-64.
17. Bull H. G., Garcia-Calvo M., Andersson S. A., Baginsky W. F., Chan H. K., Ellsworth D., Miller R., Stearns R. A., Bakshi R. K., Rasmusson G. H., Tolman R. L., Myers R. W., Kozarich J. W. and Harris G. S., Mechanism-based inhibition of human steroid 5α-reductase by finasteride: Enzyme catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J. Am. Chem. Soc. 118 (1996) 2359-2365.
18. Prahalada S., Tarantal A. F., Harris G. S., Ellsworth K. P., Clarke A. P., Skiles G. L., MacKenzie K. I., Kruk L. F., Ablin D. S., Cukierski M. A., Peter C. P., van Zwieten M. J. and Hendrickz A. G., Effects of finasteride, a type 2 5alpha-reductawe inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology 55 (1997) 119-131.
19. Levy M. A., Brandt M., Sheedy K. M., Holt D. A., Heaslip J. I., Trill J. J., Ryan P. J., Morris R. A., Garrison L. M. and Bergsma D. J., Cloning, expression and functional characterization of type 1 and type 2 steroid Salpha-reductases from cynomolgus monkey: Comparisons with human and rat isozymes. J. Steroid Biochem. Mol Biol. 54 (1995) 307-319.
20. Andersson A., Davis D. L., Dahlbäck H., Jörnvall H. and Russell D. W., Cloning, structure and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264 (1989) 8222-8229.
21. Harris G., Azzolina B., Baginsky W., Cimis G., Rasmusson G. H., Tolman R. L., Raetz C. R. H. and Ellsworth K., Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10787-10791.
22. Levy M. A., Brandt J. and Greway A. T., Mechanistic studies with solubilized rat liver steroid 5α-reductase: Elucidation of the kinetic mechanism. Biochem. 29 (1990) 2808-2815.
23. Wigley W. C., Prihoda J. S., Mowszowicz I., Mendonca B. B., New M. I., Wilson J. D. and Russell D. W., Natural mutagenesis study of the human steroid 5α-reductase 2 isozyme. Biochem. 33 (1994) 1265-1270.
24. Thigpen, A. E. and Russell, D. W., Four-amino acid segment in steroid 5α-reductase 1 confers sensitivity to finasteride, a competitive inhibitor. J. Biol. Chem., 1992, 8577-8583.
25. Normington K. and Russell D. W., Tissue distribution of kinetic characteristics of rat steroid 5α-reductase isozymes. J. Biol. Chem. 267 (1992) 19548-19554.
26. Faller B., Farley D. and Nick H., Finasteride: A slow-binding 5α-reductase inhibitor. Biochem. 32 (1993) 5705-5710.
27. Harris G. S., Ellsworth K. E., Witzel B. E. and Tolman R. L., Steroid 5α-reductase: Comparative study of mechanism of inhibition of nonsteroids Ono-3805 and LY191704. Bioorg. Chem. 24 (1996) 386-400.
28. Chan, H. K., Geissler, W. M. and Andersson, S., Characterization of human steroid 5α-reductase type 1 and 2 expressed in the baculovirus system. In Sex hormones and anti-hormones in endocrine dependent pathology: Basic and clinical aspects, ed. M. Motta and M. Serio. Elsevier Science, Amsterdam, 1994, pp. 67-76.
29. 1-4-azasteroids: Toward perfection of rates of time-dependent inhibition by using ligand binding energies. Biochem. 34 (1995) 13433-13459.
30. Bakshi R. K., Rasmusson G. H., Patel G. F., Mosley R. T., Chang B., Ellsworth K., Harris G. S. and Tolman R. L., 4-aza-3-oxo-5α-androst-1-ene-17β-N-aryl-carboxamides as dual inhibitors of human type 1 and 2 steroid 5α-reductases. Dramatic effect of N-aryl substituents on type 1 and 2 5α-reductase inhibitory potency. J. Med. Chem. 38 (1995) 3189-3192.
31. Liang T., Cascieri M., Cheung A., Reynolds G. and Rasmusson G., Species differences in prostatic steroid 5α-reductases of rat, human and dog. Endocrinol. 117 (1985) 571-579.
32. Rasmusson G., Reynolds G., Steinberg N., Walton E., Patel G., Liang T., Cascieri M., Cheung A., Brooks J. and Berman C., Azasteroids: Structure-activity relationships for inhibition of 5α-reductase and of androgen receptor binding. J. Med. Chem. 29 (1986) 2298-2315.
33. Levy M. A., Brandt M., Sheedy K. M., Dinh J. T., Holt D. A., Garrison L. M., Bergsma D. J. and Metcalf B. W., Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5α-reductase isoform 2. J. Steroid Biochem. Mol. Biol. 48 (1994) 197-206.
34. Hirsch K. S., Jones C. D. A., Andersson S., McQuaid L., Stamm N. B., Neubauer B. L., Pennington P. and Toomey R. E., LY191704: A selective, nonsteroidal inhibitor of human steroid 5α-reductase type 1. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 5277-5281.